Kaushiki Mazumdar

List of Publications by Year
in descending order

35 papers	1,154 citations	471509 17 h-index	395702 33 g-index
35 all docs	35 docs citations	35 times ranked	1750 citing authors

#	Article	IF	Citations
1	Accelerating Drug Development through Repurposed FDA-Approved Drugs for COVID-19: Speed Is Important, Not Haste. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	3
2	The Nucleocapsid Protein of SARSâ€“CoV-2: a Target for Vaccine Development. Journal of Virology, 2020, 94, .	3.4	329
3	Evaluation of Pathogenic Potentialities and Transmissibility of Aerobic and Anaerobic Bacteria in Sexually Transmitted Diseases. British Journal of Medicine and Medical Research, 2014, 4, 4533-4541.	0.2	0
4	Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis. Journal of Visualized Experiments, 2011, , .	0.3	7
5	New Patentable Use of an Old Neuroleptic Compound Thioridazine to Combat Tuberculosis: A Gene Regulation Perspective. Recent Patents on Anti-infective Drug Discovery, 2011, 6, 128-138.	0.8	27
6	Experimental analyses of synergistic combinations of antibiotics with a recently recognised antibacterial agent, lacidipine. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29, 239-243.	2.9	9
7	Potential role of the cardiovascular non-antibiotic (helper compound) amlodipine in the treatment of microbial infections: scope and hope for the future. International Journal of Antimicrobial Agents, 2010, 36, 295-302.	2.5	31
8	Visualization of Transepithelial Passage of the Immunogenic 33-Residue Peptide from Î±-2 Gliadin in Gluten-Sensitive Macaques. PLoS ONE, 2010, 5, e10228.	2.5	37
9	TLR4-independent and PKR-dependent interleukin 1 receptor antagonist expression upon LPS stimulation. Cellular Immunology, 2009, 259, 33-40.	3.0	10
10	In vitro and in vivo efficacies of amlodipine against Listeria monocytogenes. European Journal of Clinical Microbiology and Infectious Diseases, 2009, 28, 849-853.	2.9	8
11	The anti-inflammatory non-antibiotic helper compound diclofenac: an antibacterial drug target. European Journal of Clinical Microbiology and Infectious Diseases, 2009, 28, 881-891.	2.9	89
12	Noninflammatory Gluten Peptide Analogs as Biomarkers for Celiac Sprue. Chemistry and Biology, 2009, 16, 868-881.	6.0	13
13	Activity of the phenothiazine methdilazine alone or in combination with isoniazid or streptomycin against Mycobacterium tuberculosis in mice. Journal of Medical Microbiology, 2009, 58, 1667-1668.	1.8	8
14	Search for potential target site of nucleocapsid gene for the design of an epitope-based SARS DNA vaccine. Immunology Letters, 2008, 118, 65-71.	2.5	28
15	In vitro efficacy of diclofenac against Listeria monocytogenes. European Journal of Clinical Microbiology and Infectious Diseases, 2008, 27, 315-319.	2.9	17
16	The anti-inflammatory drug Diclofenac retains anti-listerial activityin vivo. Letters in Applied Microbiology, 2008, 47, 106-111.	2.2	25
17	Anti-Salmonella activity of a flavonone from Butea frondosa bark in mice. Oriental Pharmacy and Experimental Medicine, 2008, 8, 339-348.	1.2	1
18	Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice. International Journal of Antimicrobial Agents, 2007, 30, 336-340.	2.5	71

#	Article	IF	Citations
19	Potential management of resistant microbial infections with a novel non-antibiotic: the anti-inflammatory drug diclofenac sodium. International Journal of Antimicrobial Agents, 2007, 30, 242-249.	2.5	89
20	Isolation and identification of a flavone (quercetin) from Butea frondosa bark. Pharmaceutical Chemistry Journal, 2007, 41, 269-271.	0.8	12
21	Antimicrobial potentiality of the thioxanthene flupenthixol through extensive in vitro and in vivo experiments. International Journal of Antimicrobial Agents, 2006, 27, 58-62.	2.5	16
22	Assessment of antibacterial activity of the cardiovascular drug nifedipine. Oriental Pharmacy and Experimental Medicine, 2006, 6, 126-133.	1.2	8
23	Diclofenac in the management of E. coli urinary tract infections. In Vivo, 2006, 20, 613-9.	1.3	33
24	In Vitro and In Vivo Synergism between Tetracycline and the Cardiovascular Agent Oxyfedrine HCl against Common Bacterial Strains. Biological and Pharmaceutical Bulletin, 2005, 28, 713-717.	1.4	28
25	Antibacterial property of the antipsychotic agent prochlorperazine, and its synergism with methdilazine. Microbiological Research, 2005, 160, 95-100.	5.3	40
26	In vitro and in vivo antimycobacterial activity of an antihypertensive agent methyl-L-DOPA. In Vivo, 2005, 19, 539-45.	1.3	7
27	Triflupromazine: a microbicide non-antibiotic compound. Acta Microbiologica Et Immunologica Hungarica, 2004, 51, 1-15.	0.8	8
28	Studies on the antibacterial potentiality of isoflavones. International Journal of Antimicrobial Agents, 2004, 23, 99-102.	2.5	55
29	Evaluation of Synergism between the Aminoglycoside Antibiotic Streptomycin and the Cardiovascular Agent Amlodipine. Biological and Pharmaceutical Bulletin, 2004, 27, 1116-1120.	1.4	40
30	Antimycobacterial activity of the antiinflammatory agent diclofenac sodium, and its synergism with streptomycin. Brazilian Journal of Microbiology, 2004, 35, 316-323.	2.0	30
31	Phytochemical isoflavones against diabetic foot bacteria. Oriental Pharmacy and Experimental Medicine, 2004, 4, 261-266.	1.2	2
32	In vitro and in vivo antimycobacterial activity of antiinflammatory drug, diclofenac sodium. Indian Journal of Experimental Biology, 2004, 42, 922-7.	0.0	14
33	Antimicrobial potentiality of a new non-antibiotic: the cardiovascular drug oxyfedrine hydrochloride. Microbiological Research, 2003, 158, 259-264.	5.3	26
34	Antibacterial potential of an antispasmodic drug dicyclomine hydrochloride. Indian Journal of Medical Research, 2003, 118, 192-6.	1.0	7
35	Amlodipine: a cardiovascular drug with powerful antimicrobial property. Acta Microbiologica Polonica, 2003, 52, 285-92.	0.1	26